Posted by Michael Wonder on 20 Feb 2020
Canadian regulator considers changes to new drug pricing plan
20 February 2020 - Canada’s drug pricing agency is contemplating significant changes to how it will apply new regulations aimed at lowering costs, as drug makers unhappy with the policy delay introducing new medicines in the country and blame it for job cuts.
Canada in August passed the new regulations for medicines under patent protection despite heavy lobbying from drug makers that stand to lose billions in revenue.
The new rules base Canadian drug prices on those from a group of countries with lower prices than the benchmark group currently used to set price ceilings, and give regulators the power to review new medicines based on cost effectiveness.
